港股異動 | 利好疊加 四環醫藥(0460.HK)漲超4%
格隆匯1月10日丨四環醫藥(0460.HK)開盤拉昇漲超4%,現報1.53港元,總市值143億港元。公司與韓國VIOL就黃金微針達成獨家代理協議。該產品是新一代黃金微針,可以治療從淺層到深層各個層級的皮膚問題。此舉,不僅豐富和擴大了集團醫美平台的產品組合,還體現了集團的產品佈局策略更加面向多元化與國際化。另外,公司抗血栓藥替格瑞洛片(60毫克及90毫克)獲藥品註冊批件,本次該產品獲頒《藥品註冊證書》,將進一步惠及廣大患者,同時為集團的抗血栓藥物管線再添一重磅品種,利於該藥品未來的市場銷售和市場競爭,對集團的經營業績產生積極影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.